Perälä, J, Suvisaari, J, Saarni, SI, Kuoppasalmi, K, Isometsä, E, Pirkola, S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry
2007; 64: 19–28.
Schwartz, T, Stahl, S. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther
2011; 17: 110–7.
Kegels, LS, Abi-Dargham, A, Frankle, WG, Gil, R, Cooper, TB, Slifstein, M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psych
2010; 67: 231–9.
Thompson, JL, Urban, N, Slifstein, M, Xu, X, Kegeles, LS, Girgis, RR, et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry
2013; 18: 909–15.
Stahl, SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th edn.
Cambridge University Press, 2013.
Morrissette, DA, Stahl, SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr
2014; 19: 439–48.
Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment
2013; 6: 97–100.
Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand
2012; 125: 349–51.
Uchida, H, Takeuchi, H, Graff-Guerrero, A, Suzuki, T, Watanabe, K, Mamo, DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol
2011; 31: 497–502.
Uchida, H, Takeuchi, H, Graff-Guerrero, A, Suzuki, T, Watanabe, K, Mamo, DC. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol
2011; 31: 318–25.
Stahl, S, Morrissette, D. Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In Polypharmacy in Psychiatry Practice. Vol. I: Multiple Medication Use Strategies (ed Ritsner, MS): pp. 107–125. Springer Netherlands, 2013.
Kapur, S, Zipursky, R, Roy, P, Jones, C, Remington, G, Reed, K, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology
1997; 131: 148–52.
Midha, KK, Hubbard, JW, Marder, SR, Marshall, BD, Van Putten, T. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci
1994; 19: 254–64.
Remington, G, Mamo, D, Labelle, A, Reiss, J, Shammi, C, Mannaert, E, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry
2006; 163: 396–401.
de Leon, J, Sandson, NB, Cozza, KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics, Part II. Psychosomatics
2008; 48: 347–61.
Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry
1994; 151: 825–35.
Correll, CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry
2010; 25: S12–21.
Remington, G, Kapur, S. Antipsychotic dosing: how much but also how often?
2010; 36: 900–3.
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S. ‘Breakthrough’ dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci
2007; 27: 2979–86.
Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses
2010; 4: 56–73.
Robinson, DG, Woerner, MG, Alvir, JM, Geisler, S, Koreen, A, Sheitman, B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry
1999; 156: 544–9.
Längle, G, Steinert, T, Weiser, P, Schepp, W, Jaeger, S, Pfiffner, C, et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand
2012; 125: 372–81.
Essock, SM, Schooler, NR, Stroup, TS, McEvoy, JP, Rojas, I, Jackson, C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry
2011; 168: 702–8.
Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract
2008; 62: 1237–45.
Volavka, J, Czobor, P, Nolan, K, Sheitman, B, Lindenmayer, JP, Citrome, L, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol
2004; 24: 225–8.
Volavka, J, Citrome, L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull
2011; 37: 921–9.
Lopez, L, Kane, J. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. J Clin Psychiatry
2015; 76: 1249–50.
Stahl, SM, Morrissette, DA, Citrome, L, Saklad, SR, Cummings, MA, Meyer, JM, et al. ‘Meta-guidelines’ for the management of patients with schizophrenia. CNS Spectr
2013; 18: 150–62.
Stahl, SM. Antipsychotic polypharmacy, part I: therapeutic option or dirty little secret?
J Clin Psychiatry
1999; 60: 425–6.
Stahl, SM. Antipsychotic polypharmacy, part II: tips on use and misuse. J Clin Psychiatry
1999; 60: 506–7.
Stahl, SM. Antipsychotic polypharmacy: squandering precious resources?
J Clin Psychiatry
2002; 63: 93–4.
Stahl, SM, Grady, MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Cur Med Chem
2004; 11: 313–26.
Stahl, SM. Focus: antipsychotic polypharmacy – evidence based prescribing or prescribing based evidence?
Int J Neuropsychopharmacol
2004; 7: 113–6.
Stahl, SM, Grady, M. High cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv
2004; 57: 127–9.
Stahl, SM. Antipsychotic polypharmacy: evidence based or eminence based?
Acta Psychiatr Scand
2002; 106: 321–2.
Stahl, SM, Freudenreich, O, Goff, D. A successful antipsychotic combination trial. Quo Vadis?
Acta Psychiatr Scand
2004; 110: 241–2.
Suzuki, T, Uchida, H, Tanaka, KF, Nomura, K, Takano, H, Tanabe, A, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol
2004; 7: 133–42.
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull
2009; 35: 443–57.
Davis, JM, Chen, N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol
2004; 24: 192–208.
Mauri, MC, Volonteri, LS, Colasanti, A, Fiorentini, A, De Gaspari, IF, Bareggi, SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet
2007; 46: 359–88.
Barnes, TR, Paton, C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs
2011; 25: 383–99.